Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03222674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 15, 2025 to Dec 31, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v8
  2. Study sites: 3 to 1
    • Collaborators shortened, about 11 words
    v7
  3. Primary completion date: Dec 31, 2019 to Jun 30, 2028
    • Start date: Jul 15, 2017 to Jul 15, 2025
    • Study completion date: Dec 31, 2020 to Dec 31, 2028
    v6
  4. Interventions: Muc1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (Biological) to Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (Biological)
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 1 word
    v5
  5. Study sites: 1 to 3v4 Show 5 more changesShow less
    • Interventions: Muc1/CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cells (Biological) to Muc1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (Biological)
    • Study description shortened, about 21 words
    • Collaborators expanded, about 11 words
    • Eligibility criteria shortened, about 1 word
    • Study title expanded, about 1 word
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Interventions: CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cells (Biological) to Muc1/CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cells (Biological)
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 2 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.
Trial Details
NCT Number NCT03222674
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov